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MART-1-specific T cells seem to be 
capable of antigen clearance in only a 
portion of the patients. Another char-
acteristic of Melan-A/MART-1-specific 
T cells is reflected in their ability to 
generate T cells—an uncommon fea-
ture among tumor-specific T cells. 
Despite the theor etical hazard of 
adverse side effects, targeting melano-
cyte differentiation antigens appears to 
be advantageous. However, to achieve 
a more widespread application in 
treating cancer, other targets must be 
considered. To this end, a recent study 
used bone marrow–derived T cells 
stimulated with peptides from Her-2/
neu, MUC1, and heparanase to treat 
breast cancer patients (Schuetz et al., 
2009), demonstrating the feasibility 
of ACT with T cells that target more 
universal antigens (e.g., antigens rep-
resenting proteins that play important 
roles in cancer cell survival) and there-
by minimizing the risk of antigen loss 
variants (Andersen et al., 2005).
The data presented by Khammari et 
al. in this issue demonstrate that ACT 
based on PBMC-derived T cells can 
induce clinically relevant responses in 
the absence of lymphodepleting con-
ditioning, and this report represents an 
important step toward a wider applicabil-
ity of ACT. Future studies should address 
whether the clinical efficacy of PBMC-
based ACT in melanoma is restricted to 
early disease. In any case, Khammari 
et al. present evidence that ACT can be 
used to treat solid tumors in a less inten-
sive setting, with limited side-effects and 
potential clinical efficacy.
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Analyzing the cost of Preventing 
nonmelanoma Skin cancer
Sallyann Coleman King1 and Suephy Chen1,2
In this issue, Gordon et al. report a novel study evaluating the 
cost-effectiveness of promoting sunscreen use to prevent actinic keratoses 
and nonmelanoma skin cancer. This cost-effectiveness analysis (cEA) provides 
important data for health policy makers facing decisions regarding sunscreen 
education campaigns and sets the stage for future prevention-targeted cEAs. 
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Nonmelanoma skin cancer (squamous 
and basal cell carcinoma) is unique 
in that we know the major factor (i.e., 
UVR) that contributes to its devel-
opment. Therefore, it is possible to 
take measures to prevent the inciting 
events from occurring.
The goal of disease prevention is 
to reduce morbidity and mortality. 
Whereas secondary prevention aims 
at early detection and treatment and 
tertiary prevention aims to reduce the 
negative impact of disease, the goal 
of primary prevention is to avoid dis-
ease development entirely. With the 
direct and indirect costs of actinic 
keratoses and nonmelanoma skin 
cancer exceeding $3.5 billion in the 
United States (Bickers et al., 2006), 
primary prevention of skin cancer 
via sun protective measures is a key 
focus for educational efforts of the 
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American Academy of Dermatology 
(2009) and the Centers for Disease 
Control and Prevention (Saraiya et 
al., 2004). Although the most effec-
tive way to prevent skin cancer is 
through sun avoidance and wearing 
protective clothing, these measures 
are not always practical. Therefore, 
the use of sunscreens is an important 
sun protection method advised by 
dermatologists.
In animal models, sunscreens have 
been shown to prevent UVR-induced 
damage (Kligman, 1989). Most sun-
screens effectively absorb UVB, and 
broad-spectrum sunscreens, which fil-
ter both UVB and UVA, have recently 
become readily available (Gonzalez 
et al., 2008). Patients are aware of the 
benefits of sunscreen use, but many 
do not apply enough sunscreen for 
an ideal sun protection factor to be 
achieved (Bech-Thomsen and Wulf, 
1992; Neale et al., 2002). Moreover, 
they often do not reapply sunscreens 
effectively after sweating, water 
immersion, or rubbing (Davis et al., 
2002), and many erroneously believe 
that sunscreens allow them to spend 
a greater amount of time in the sun 
(McLean and Gallagher, 1998). These 
behaviors and misconceptions beg the 
question: should investments be made 
to better inform the public about 
sunscreen use?
Until now, there has been no rigor-
ous, large-scale study to evaluate the 
cost effectiveness of promoting sun-
screen use. As the costs of health care 
continue to rise, it is paramount to use 
cost-effectiveness analyses (CEAs) to 
determine which programs give the 
best return on investment (i.e., which 
are the most effective in prevent-
ing and treating disease). Although 
researchers in the field of dermatology 
have recently embraced this health 
economic technique, as yet no useful 
dermatology CEAs exist.
Evaluating the costs and benefits of 
sunscreen use on a population level 
provides evidence to inform decisions 
about whether to pursue policies sup-
porting sunscreen-based prevention 
measures. In this issue, Gordon et al. 
report a single-blinded randomized 
trial of a cohort of approximately 
1,300 Australians over a 5-year period, 
in which the researchers sought to 
evaluate the cost effectiveness of an 
intervention advising the daily appli-
cation of sunscreen versus the usual 
discretionary recommendations. The 
investigators reported an additional 
cost of $106,449 was required to 
prevent 11 basal-cell carcinomas, 24 
squamous-cell carcinomas, and 838 
actinic keratoses (AKs) among 812 
residents over 5 years, compared with 
the cost of discretionary sunscreen 
use. This additional cost included 
sunscreens, nurse telephone calls to 
reinforce behavior, participant costs 
(time), provider costs (salaries, office, 
consumables), costs of voluntary con-
tributions (unpaid staff), and the cost 
of treating the diagnosed AKs and 
skin cancers. Averaged out, an annual 
investment of $0.74 per person was 
conservatively estimated to have the 
potential to save the government or 
health care payer $88,203 ($109 per 
person) over the same period. This sug-
gested that the expenditure is a sound 
investment. (The estimate assumed 
treatment of 50% of AKs; however, the 
cost savings remained even if all AKs 
were assumed to be treated.)
The authors indicate that sums far 
exceeding even the upper per-person 
confidence limit for this study are 
invested in vaccine prevention against 
human papillomavirus and rotavirus. 
Our caveat to this assertion is that pre-
ventative vaccine measures are virtu-
ally complete upon injection, whereas 
sunscreen interventions require alter-
ing human behavior—which has been 
repeatedly demonstrated to be difficult 
and sometimes short lived. Cases in 
point include tobacco cessation and 
wearing helmets and seatbelts. Patient 
adherence to behaviors that supposedly 
improve health is not as straightforward 
as health professionals would hope.
Even with these drawbacks in 
mind, this CEA provides important 
data for health policy makers when 
deciding whether to implement cam-
paigns that advocate sunscreen use. 
This study also sets the stage for future 
prevention-targeted studies, allow-
ing a comparison of its findings to 
those of other prevention efforts. For 
example, it would be interesting to 
compare the results of Gordon et al. 
with those of other population efforts 
to promote sun avoidance, such as 
providing shade structures in open 
spaces or the promotion of protective 
clothing during recreational activities. 
It is important that we continue to dis-
cover ways to prevent skin cancer and 
at the same time encourage the use of 
CEAs to evaluate the fiscal soundness 
of all new technologies.
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|Sunscreen  promotion and use  is cost effective.
